Literature DB >> 11567222

Frequent and early loss of the EGR1 corepressor NAB2 in human prostate carcinoma.

S A Abdulkadir1, J M Carbone, C K Naughton, P A Humphrey, W J Catalona, J Milbrandt.   

Abstract

The transcription factor EGR1 is frequently overexpressed in human prostate cancer and regulates the expression of several genes important for tumor progression. In addition, mice lacking the Egr1 gene show a defect in prostate tumorigenesis. NAB2 is a novel corepressor molecule that modulates EGR1 activity and is induced by the same stimuli that induce EGR1. The human NAB2 gene has been localized to 12q13.3-14.1, within a chromosomal region that is thought to harbor a prostate tumor suppressor. We have examined the expression of NAB2 in human prostate carcinoma specimens. We show here that NAB2 protein expression is lost in a majority of primary prostate carcinoma specimens, including many samples that have high EGR1 levels. This loss occurs early in the tumorigenic process and is sustained, as it is seen in precursor prostatic intraepithelial neoplasia lesions as well as in metastases. Furthermore, loss of NAB2 did not correlate with the tumor grade or stage. Our findings suggest that high levels of EGR1 coupled with low levels of NAB2 can result in high, unrestrained EGR1 transcriptional activity in human prostate cancers. Copyright 2001 by W.B. Saunders Company

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11567222     DOI: 10.1053/hupa.2001.27102

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  26 in total

1.  EGR1, EGR2, and EGR3 activate the expression of their coregulator NAB2 establishing a negative feedback loop in cells of neuroectodermal and epithelial origin.

Authors:  Joerg Kumbrink; Kathrin H Kirsch; Judith P Johnson
Journal:  J Cell Biochem       Date:  2010-09-01       Impact factor: 4.429

Review 2.  Ca2+ as a therapeutic target in cancer.

Authors:  Scott Gross; Pranava Mallu; Hinal Joshi; Bryant Schultz; Christina Go; Jonathan Soboloff
Journal:  Adv Cancer Res       Date:  2020-07-09       Impact factor: 6.242

3.  Changes in differential gene expression because of warm ischemia time of radical prostatectomy specimens.

Authors:  Atreya Dash; Ira P Maine; Sooryanarayana Varambally; Ronglai Shen; Arul M Chinnaiyan; Mark A Rubin
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

Review 4.  Cancer biology and NuRD: a multifaceted chromatin remodelling complex.

Authors:  Anne Y Lai; Paul A Wade
Journal:  Nat Rev Cancer       Date:  2011-07-07       Impact factor: 60.716

5.  Regulation of p130(Cas)/BCAR1 expression in tamoxifen-sensitive and tamoxifen-resistant breast cancer cells by EGR1 and NAB2.

Authors:  Joerg Kumbrink; Kathrin H Kirsch
Journal:  Neoplasia       Date:  2012-02       Impact factor: 5.715

Review 6.  The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin.

Authors:  V Baron; E D Adamson; A Calogero; G Ragona; D Mercola
Journal:  Cancer Gene Ther       Date:  2006-02       Impact factor: 5.987

7.  Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma.

Authors:  J Wang; J Kim; M Roh; O E Franco; S W Hayward; M L Wills; S A Abdulkadir
Journal:  Oncogene       Date:  2010-02-08       Impact factor: 9.867

8.  Interaction of Nkx3.1 and p27kip1 in prostate tumor initiation.

Authors:  Bernard Gary; Ricardo Azuero; Gayatree S Mohanty; Walter C Bell; Isam-Eldin A Eltoum; Sarki A Abdulkadir
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

9.  Dynamics of Protein Expression Reveals Primary Targets and Secondary Messengers of Estrogen Receptor Alpha Signaling in MCF-7 Breast Cancer Cells.

Authors:  Andrei P Drabovich; Maria P Pavlou; Christina Schiza; Eleftherios P Diamandis
Journal:  Mol Cell Proteomics       Date:  2016-04-11       Impact factor: 5.911

10.  Androgen deprivation therapy induces androgen receptor-dependent upregulation of Egr1 in prostate cancers.

Authors:  Bin Xu; Gusheng Tang; Chengwu Xiao; Linhui Wang; Qing Yang; Yinghao Sun
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.